Gene sequencing result determination and analysis is the systematic process of converting raw sequence reads into accurate, interpretable biological information through validated bioinformatics workflows and rigorous quality control. Performed in accredited third-party laboratories under frameworks such as ISO/IEC 17025 and ISO 15189, this analytical discipline underpins clinical diagnostics, oncology, infectious disease surveillance, and agricultural genomics. This guide explains the complete analytical workflow, sample requirements, testing items, methods, and practical applications of sequencing result analysis.
Technical Overview
Gene sequencing result determination and analysis refers to the end-to-end process of assessing raw sequencing data quality, aligning reads to reference genomes, detecting genetic variants, annotating biological significance, and issuing interpretable reports. Modern sequencing platforms generate massive volumes of base calls, and the value of sequencing lies not in data generation itself but in the accuracy and reliability of the analytical pipeline that transforms those data into actionable conclusions.
A typical analytical workflow consists of five core stages: (1) primary analysis, in which instrument signals are converted into base calls with associated quality scores; (2) secondary analysis, involving quality filtering, adapter trimming, read alignment, and variant calling; (3) tertiary analysis, which includes variant annotation, filtering against population databases, and clinical or biological interpretation; (4) validation, in which significant findings are confirmed using orthogonal methods such as Sanger sequencing; and (5) reporting, structured according to professional guidelines such as ACMG/AMP recommendations for variant classification.
Quality determination is embedded at every stage. Key performance metrics include Q-score distributions (Q30 indicating a 99.9% base call accuracy), mean sequencing depth, genome coverage uniformity, mapping rate, duplication rate, strand bias, and variant allele frequency. Laboratories operating under ISO/IEC 17025 and ISO 15189 must demonstrate analytical validity, including sensitivity, specificity, precision, and limit of detection, before clinical or commercial reporting of results.
Testing Samples
Human Blood and Buccal Samples
Peripheral blood collected in EDTA tubes and buccal swabs are the most common sample types for germline genetic testing, including inherited disease screening, carrier testing, and pharmacogenomics. Genomic DNA is extracted and assessed for concentration, purity (A260/A280 ratio of 1.8–2.0), and integrity before library preparation. A minimum input of typically 50–200 ng of high-quality DNA is required for most applications, depending on platform and assay design.
Tumor Tissue Samples
Fresh-frozen tissue and formalin-fixed paraffin-embedded (FFPE) blocks are used for somatic variant analysis in oncology. FFPE samples require specialized pre-analytical treatment because formalin fixation causes DNA fragmentation and cytosine deamination artifacts. Tumor content, typically required to be above 20% for solid tumor panels, and DNA fragment size distribution are critical quality determination parameters before sequencing proceeds.
Cell-Free DNA Samples
Plasma-derived circulating cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) are analyzed for liquid biopsy applications. These samples demand stringent handling: blood must be processed within 2–4 hours or collected in specialized stabilizing tubes, and the extracted cfDNA must be evaluated for fragment size, with a mono-nucleosomal peak around 160–180 bp indicating acceptable quality. Given low input quantities, unique molecular identifiers are frequently used to suppress sequencing and PCR errors.
Microbial Samples
Bacterial isolates, viral strains, stool specimens, and environmental swabs are submitted for whole-genome microbial sequencing, metagenomic analysis, antimicrobial resistance genotyping, and outbreak tracing. Pre-analytical determination includes culture purity assessment, nucleic acid quantification, and host DNA depletion for direct-from-sample metagenomic workflows.
Plant, Animal, and Prenatal Samples
Testing Items
The scope of result determination depends on the assay type and client requirements. Core analytical items include:
- Sequencing quality determination: per-base quality scores, Q30 percentage, GC bias, adapter contamination, and read length distribution.
- Alignment and mapping analysis: mapping rate, properly paired read percentage, insert size distribution, and coverage depth statistics.
- Single nucleotide variants (SNVs) and small insertions/deletions (InDels): detection, genotyping, and allele frequency quantification.
- Copy number variations (CNVs): gene-level and exon-level dosage changes determined from depth-of-coverage analysis.
- Structural variants (SVs) and gene fusions: large rearrangements, translocations, and fusion transcripts detected through discordant read pairs and split-read algorithms.
- Variant annotation and classification: cross-referencing against ClinVar, gnomAD, COSMIC, and professional databases; pathogenicity grading according to ACMG/AMP five-tier criteria.
- Microbial analysis: species identification, serotyping, virulence gene detection, antimicrobial resistance determinants, and phylogenetic relatedness.
- Specialized determinations: STR profiling, HLA typing, mitochondrial genome analysis, and methylation/epigenetic status.
Testing Methods
Sanger Sequencing
Sanger sequencing, based on capillary electrophoresis of chain-terminated fragments, remains the reference method for targeted determination of short DNA regions. It delivers read lengths of 500–1,000 bp with accuracy exceeding 99.9% for single-pass reads and is routinely used to confirm variants initially detected by next-generation sequencing, resolve ambiguous NGS calls, and validate family segregation studies.
Next-Generation Sequencing (NGS)
Short-read massively parallel sequencing platforms support whole-genome sequencing (WGS), whole-exome sequencing (WES), and targeted gene panels. Analysis includes quality control with tools such as FastQC, alignment to the reference genome using BWA-MEM or similar algorithms, duplicate marking, base quality recalibration, and variant calling with toolkits such as GATK. Targeted panels typically achieve sequencing depths of 500× to 5,000× for somatic applications, while germline WGS is generally reported at 30× or greater mean depth.
Long-Read and Third-Generation Sequencing
Pacific Biosciences HiFi sequencing and Oxford Nanopore technologies generate reads ranging from kilobases to megabases, enabling resolution of complex structural variants, repetitive regions, phasing of haplotypes, and full-length transcript analysis. Nanopore sequencing additionally supports direct detection of base modifications such as methylation without bisulfite conversion.
Bioinformatics Pipeline and Data Determination
The analytical pipeline operates within validated computing environments with version-controlled software and reference databases. Determination criteria are pre-defined in standard operating procedures, including minimum coverage thresholds (for example, 20× for germline reporting or 100× for low-frequency somatic variants), minimum variant allele frequency cutoffs, minimum base quality and mapping quality scores, and strand-support requirements. Every pipeline run includes positive, negative, and no-template controls, and reference materials such as those from the NIST Genome in a Bottle program are used to monitor ongoing analytical performance.
Validation and Confirmation
Findings with clinical significance are confirmed through orthogonal methodologies, most commonly Sanger sequencing for SNVs and InDels, or quantitative PCR and chromosomal microarray analysis for CNVs. Method validation follows ISO/IEC 17025 and ISO 15189 requirements, with documented performance characteristics for accuracy, precision, reproducibility, reportable range, and limit of detection. National technical standards, including GB/T 37874 concerning general requirements for nucleic acid sequence analysis, further define quality expectations for sequencing laboratories.
Applications
Gene sequencing result determination supports a wide spectrum of clinical, research, and industrial uses:
- Clinical oncology: comprehensive genomic profiling of tumors to guide targeted therapy selection, detection of acquired resistance mutations through liquid biopsy monitoring, and assessment of tumor mutational burden and microsatellite instability for immunotherapy prediction.
- Inherited disease diagnosis: identification of pathogenic variants underlying Mendelian disorders, carrier screening for reproductive planning, rapid whole-genome sequencing for critically ill neonates, and preimplantation genetic testing during IVF.
- Infectious disease management: pathogen identification directly from clinical specimens, genomic epidemiology for outbreak investigation, tuberculosis transmission tracking, and genotypic prediction of antiviral and antibiotic resistance.
- Pharmacogenomics: determination of CYP450 family and other drug-metabolizing enzyme genotypes to individualize drug selection and dosing.
- Transplantation and immunology: high-resolution HLA typing for donor-recipient matching and STR-based engraftment monitoring.
- Agriculture and food safety: molecular marker-assisted breeding, seed purity and variety authenticity verification, GMO event detection, and foodborne pathogen source tracing.
- Forensic and identity testing: STR-based human identification, kinship determination, and mitochondrial DNA analysis for degraded samples.
- Basic and translational research: de novo genome assembly, population genetic diversity studies, and gene expression profiling through RNA sequencing.
FAQ
How accurate are gene sequencing results?
With validated pipelines, consensus accuracy for germline variant detection typically exceeds 99.9% in adequately covered regions, and Sanger confirmation adds further confidence for clinically significant findings. Accuracy depends on sample quality, sequencing depth, and adherence to pre-defined determination criteria. Accredited laboratories monitor false-positive and false-negative rates continuously using reference materials.
How long does sequencing analysis take?
Turnaround time varies by application: Sanger-based targeted testing may be completed within 3–7 working days, targeted NGS panels generally require 7–14 calendar days, and comprehensive whole-genome or whole-exome analyses may take 2–4 weeks including interpretation and reporting.
What sample quality is required for reliable results?
Genomic DNA should meet minimum concentration thresholds, exhibit A260/A280 ratios between 1.8 and 2.0, and show limited fragmentation. FFPE-derived DNA requires shorter fragment library protocols, while cfDNA must show the expected nucleosomal size distribution. Laboratories perform pre-analytical QC and will request re-sampling when quality metrics fall below validated thresholds.
What is the difference between WGS, WES, and targeted panel sequencing?
WGS sequences the entire genome, including non-coding regions, providing the broadest determination scope at approximately 30× mean depth. WES focuses on protein-coding exons at higher depth, typically 100×, covering most known disease-causing variants. Targeted panels interrogate selected genes at very high depth, often 500× or greater, delivering maximal sensitivity for low-allele-frequency variants in known disease genes.
Do NGS findings need to be confirmed by another method?
For research use, pipeline-based results are generally sufficient when QC criteria are met. For clinical reporting, significant variants—particularly novel or low-coverage calls—are routinely confirmed by Sanger sequencing or an alternative orthogonal method in accordance with professional guidelines and laboratory validation policies.
How are variants classified and reported?
Sequence variants are annotated against curated databases and classified using the five-tier ACMG/AMP framework: pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, and benign. Reports state the detection method, genomic coordinates, transcript references, zygosity, allele frequency, classification rationale, and any recommended confirmatory testing.